Edition:
India

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Global Market

8.25USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$8.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,636
52-wk High
$107.50
52-wk Low
$7.90

Latest Key Developments (Source: Significant Developments)

InVivo Therapeutics Announces Latest Results From INSPIRE
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES LATEST RESULTS FROM INSPIRE AND PROVIDES UPDATE ON PROPOSED CLINICAL PATH FORWARD.INVIVO THERAPEUTICS HOLDINGS - 19 PATIENTS IMPLANTED WITH NEURO-SPINAL SCAFFOLD;3 PATIENTS DIED WITHIN 2 WEEKS OF IMPLANTATION​ IN STUDY.INVIVO THERAPEUTICS HOLDINGS CORP - ‍16 EVALUABLE PATIENTS HAVE NOW ALL REACHED SIX-MONTH PRIMARY ENDPOINT VISIT IN STUDY​.INVIVO THERAPEUTICS - ‍DOES NOT ANTICIPATE REOPENING ENROLLMENT IN INSPIRE,EXPECTS TO PROVIDE ADDITIONAL CLARITY ON CLINICAL PATH FORWARD IN Q2 2018​.  Full Article

InVivo Therapeutics Announces Executive Management And Board Changes
Monday, 18 Dec 2017 

Dec 18 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES EXECUTIVE MANAGEMENT AND BOARD CHANGES.INVIVO THERAPEUTICS HOLDINGS CORP - ‍RICHARD TOSELLI, NAMED ACTING CHIEF EXECUTIVE OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI REPLACES MARK PERRIN, WHO HAS RESIGNED AS CEO AND CHAIRMAN OF INVIVO'S BOARD OF DIRECTORS​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI WILL CONTINUE TO SERVE IN HIS CAPACITY AS INVIVO'S CHIEF MEDICAL OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ANN MERRIFIELD WAS APPOINTED AS CHAIR OF BOARD OF DIRECTORS​.  Full Article

InVivo Therapeutics reports Q3 loss per share $0.28
Tuesday, 31 Oct 2017 

Oct 30 (Reuters) - InVivo Therapeutics Holdings Corp :InVivo Therapeutics provides business update and reports 2017 third quarter financial results.Q3 adjusted loss per share $0.19 excluding items.Q3 loss per share $0.28.  Full Article

Invivo Therapeutics Holdings Q2 loss per share $0.16
Friday, 5 Aug 2016 

Invivo Therapeutics Holdings Corp : Invivo Therapeutics reports 2016 second quarter financial results and business update . Q2 loss per share $0.16 . Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S .Q2 adjusted loss per share $0.18 excluding items.  Full Article

InVivo receives investigational testing authorization from Health Canada
Wednesday, 13 Jul 2016 

InVivo Therapeutics Holdings Corp :Receives investigational testing authorization from Health Canada.  Full Article

Invivo Therapeutics says Christina Morrison appointed as chairwoman of audit committee
Thursday, 9 Jun 2016 

Invivo Therapeutics Holdings Corp - :Effective June 7, 2016, Christina Morrison was also appointed to serve as chairwoman of audit committee of board.  Full Article

Invivo Therapeutics Holdings Q1 loss per share $0.24
Saturday, 7 May 2016 

Invivo Therapeutics Holdings Corp : Invivo Therapeutics reports 2016 first quarter financial results and business update .Q1 loss per share $0.24.  Full Article

BRIEF-Invivo Therapeutics Announces Reverse Stock Split

* ANTICIPATES REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 5:00 P.M. EASTERN TIME ON APRIL 16, 2018